BGB-16673, a first-in-class BTK degrader, is being studied for relapsed or refractory persistent lymphocytic leukemia (CLL) in a part 1 trial, in keeping...
Survivorship can imply one thing totally different to everybody, and it is very important mirror on the totally different definitions of survivorship, particularly...